A rather shameless attempt to capitalize on Medivation's AD woes by this swiss company:
>>Anavex comments on failure of Pfizer and Medivation's Alzheimer's investigational drug Dimebon during Phase 3 clinical trials
Last update: 3/3/2010 3:32:00 PM
GENEVA, SWITZERLAND, March 3, 2010 /PRNewswire via COMTEX/ -- Anavex Life Sciences Corp. ("ANAVEX") (AVXL) today issued a statement following today's announcement from Pfizer and Medivation (MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials.
"While this is disappointing for the Alzheimer's community, there have been many doubts expressed about Dimebon. These doubts have been documented by leading scientists, including ex-National Institutes of Health (NIH) staffers. This failure of Dimebon, which was hypothesized to act as a mitochondrial pore blocker, on top of the repeated failures of every drug studied for removing beta amyloid from the brain as a way to manage Alzheimer's disease, suggests that novel mechanisms of action that attempt to modify the disease itself, rather than treat symptoms, are necessary," said Cameron Durrant, MD, MBA, Executive Chairman of the ANAVEX Board of Directors.
ANAVEX is preparing to enter Phase 1 clinical trials with ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease, later this year.
ANAVEX 2-73 is a first of a new class of oral, disease-modifying drugs for the treatment of Alzheimer's disease, which employ an approach that targets neither amyloid, nor tau, nor mitochondrial pore blockade.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. () is a publicly traded biopharmaceutical company engaged in the discovery and development of novel drug candidates for the treatment of cancer and neurological diseases such as Alzheimer's, epilepsy, depression and pain. The company's proprietary SIGMACEPTOR(TM) Discovery Platform involves the rational design of drug compounds that fulfill specific criteria and are targeted to specific receptors involved in the modulation of multiple cellular biochemical signaling pathways.
ANAVEX's SIGMACEPTOR(TM)-N program involves the development of novel and original drug candidates that target neurological and neurodegenerative diseases (Alzheimer's disease, epilepsy, depression, pain). The company's lead drug candidates exhibit high, non-exclusive affinity for sigma receptors, which have been extensively documented as potentially valuable drug targets and have demonstrated evidence for anti-amnesic and neuroprotective properties. The company is developing non-amyloid focused approaches to disease modification in Alzheimer's disease. ANAVEX 1-41 and ANAVEX 2-73 modulate sigma receptors, a unique class of receptor molecules, to guard against oxidative stress and work through alternative mitochondrial pathways via ion channel signalling. So far the compounds have performed extremely well in well-recognized animal models of Alzheimer's disease, underscoring the promise of the company's new alternative approach to the disease.
ANAVEX's SIGMACEPTOR(TM)-C program involves the development of novel and original drug candidates targeting cancer. The company's lead drug candidates exhibit high, non-exclusive affinity for sigma receptors with strong evidence for selective pro-apoptotic, anti-metastatic and low toxicity properties in various types of solid cancers. ANAVEX 7-1037 has already demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies.<<
I must say, his take on Dimebon & AD echoes mine, but this still seems a bit tacky.
So what does their wonderful (hey, Pfizer! Over here!) drug target? The sigma-1 receptor.
anavex.com
They are not alone with this target. A Japanese company, apparently more circumspect about Dimebon's failure is also in the hunt:
m-sci.com
What's more, they are well into P2 and are partnered with Eisai.
m-sci.com
OK, Dr. Durrant, your drug is behind, so how is it better?
Cheers, Tuck |
